tiprankstipranks
Trending News
More News >
Theravance Biopharma (TBPH)
:TBPH
Advertisement

Theravance Biopharma (TBPH) AI Stock Analysis

Compare
311 Followers

Top Page

TBPH

Theravance Biopharma

(NASDAQ:TBPH)

Rating:57Neutral
Price Target:
$11.00
▼(-0.81% Downside)
Theravance Biopharma's stock score reflects a mixed outlook. Financial stabilization and strategic advancements, such as the milestone payment from Viatris, are positive. However, ongoing profitability challenges and valuation concerns limit the score. Technical indicators suggest potential for upward momentum, but increased operating expenses and pending litigation remain risks.
Positive Factors
Financial Health
Theravance Biopharma's robust financial position with no debt and a strong cash position provides downside support.
Market Expansion
Yupelri has been approved for COPD in China, ahead of expectations, potentially boosting market presence and sales.
Strategic Partnerships
Theravance Biopharma's partnership with Viatris in China, where Viatris has a substantial commercial presence, is expected to benefit Yupelri sales.
Negative Factors
Market Competition
Currently available treatments for neurogenic orthostatic hypotension and multiple systemic atrophy have poor efficacy and safety profiles, highlighting the market's challenges.
Regulatory Approval Risks
Ampreloxetine's ability to capture market share is contingent on positive results from the CYPRESS study, introducing an element of uncertainty.

Theravance Biopharma (TBPH) vs. SPDR S&P 500 ETF (SPY)

Theravance Biopharma Business Overview & Revenue Model

Company DescriptionTheravance Biopharma (TBPH) is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule medicines designed to help patients suffering from serious conditions. The company primarily operates in the pharmaceutical sector, with a core emphasis on respiratory diseases, gastrointestinal disorders, and infectious diseases. Theravance Biopharma leverages its proprietary technology platforms to develop innovative therapeutics aimed at addressing unmet medical needs.
How the Company Makes MoneyTheravance Biopharma generates revenue through the development and commercialization of pharmaceutical products. The company earns money from product sales, collaborative agreements, and licensing arrangements. Key revenue streams include sales of its FDA-approved medications and income from strategic partnerships with larger pharmaceutical companies for the co-development and commercialization of its drug candidates. These partnerships often entail upfront payments, milestone payments based on development or regulatory achievements, and royalties on sales of co-developed products. Theravance Biopharma's financial performance is also influenced by its investment in research and development, aiming to expand its pipeline and bring new therapies to market.

Theravance Biopharma Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 12.02%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Positive
Theravance Biopharma reported strong financial and operational performance, with notable growth in YUPELRI sales and Trelegy milestones. Despite some challenges related to increased operating expenses and pending litigation, the company's overall financial health and strategic advancements position it well for future success.
Q1-2025 Updates
Positive Updates
Strong Performance and Growth of YUPELRI
YUPELRI delivered solid results in the quarter with net sales increasing 6% to just over $58 million. Hospital doses increased 48% year on year, marking the strongest quarter launched to date in the hospital setting.
Trelegy Sales and Milestone Progress
GSK reported Trelegy global net sales up 14%, putting the company on track to achieve a $50 million milestone in 2025. Consensus estimates for 2025 and 2026 sales have increased by approximately $100 million since the last earnings call.
Financial Strength and Cash Position
Theravance ended the quarter with $131 million in cash and no debt, reflecting a strong financial position.
Advancement in Ampreloxetine Trials
Significant progress in the Sypris Phase III trial for ampreloxetine, with enrollment expected to complete by late summer and top-line data available approximately six months later.
Potential Long-term Value from Trelegy Royalties
Royalties from Trelegy expected to return in 2029 with significant value anticipated due to strong brand performance.
Negative Updates
Increased Operating Expenses
Operating expenses, excluding share-based compensation, increased to $25 million this quarter, driven by increased Cypress patient enrollment and incremental NDA and regulatory activity.
Pending Litigation for YUPELRI
Settlement reached with five of eight paragraph four filers, with three litigations still outstanding.
One-time Tax Payment Impacting Cash Burn
A one-time tax payment in Q2 related to the $50 million TRELEGY milestone will reflect a temporary increase in cash burn.
Company Guidance
During the Theravance Biopharma First Quarter 2025 Conference Call, the company provided various metrics and guidance. YUPELRI's net sales increased by 6% to over $58 million, driven by demand growth and favorable pricing. Hospital doses rose by 48% year-over-year. The company is advancing the Sypris trial, expecting to enroll the final patient by late summer with top-line data six months later. Theravance also highlighted the potential for a $25 million milestone if YUPELRI sales reach $250 million and a $7.5 million milestone for approval in China. Trelegy sales grew 14% globally, with expectations to achieve a $50 million milestone from Royalty Pharma in 2025. The quarter ended with $131 million in cash. The company anticipates a decline in R&D costs later in the year and expects cash burn to improve, excluding a one-time tax payment related to the Trelegy milestone.

Theravance Biopharma Financial Statement Overview

Summary
Theravance Biopharma is showing signs of financial stabilization with positive cash flow and revenue growth. However, the company continues to face profitability challenges, as indicated by persistent net losses. The balance sheet reflects a healthier equity position, providing a foundation for potential future growth.
Income Statement
45
Neutral
The company has shown some revenue growth, with a 13.65% increase from 2023 to 2024 and a 1.38% growth from 2024 to TTM (Trailing-Twelve-Months). However, consistent negative net income and EBIT indicate ongoing operational challenges. The gross profit margin is strong at 100% for TTM, but the net profit margin remains negative due to high operating expenses relative to revenue.
Balance Sheet
50
Neutral
The company has improved its equity position, moving from negative to positive stockholders' equity, which is a positive sign. The debt-to-equity ratio is 0.29 for TTM, indicating manageable leverage. However, the consistent negative net income has impacted return on equity, which remains negative.
Cash Flow
55
Neutral
The company has significantly improved its free cash flow, turning positive in TTM from negative in previous years. The operating cash flow to net income ratio is negative due to negative net income, but free cash flow has improved due to better management of operating expenses and capital expenditures.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue64.38M57.42M51.35M55.31M71.86M
Gross Profit64.38M57.42M44.76M48.02M-189.10M
EBITDA-38.45M-42.66M-79.86M-249.39M-294.00M
Net Income-56.42M-55.19M-92.82M-199.43M-278.02M
Balance Sheet
Total Assets354.16M382.00M607.40M374.82M469.06M
Cash, Cash Equivalents and Short-Term Investments88.35M102.43M327.48M173.47M292.94M
Total Debt49.82M49.16M74.12M652.08M647.06M
Total Liabilities178.62M169.00M165.60M713.39M772.81M
Stockholders Equity175.54M213.00M441.80M-338.57M-303.75M
Cash Flow
Free Cash Flow-11.87M-29.48M-187.56M-211.26M-257.02M
Operating Cash Flow-11.54M-27.00M-186.99M-207.86M-250.40M
Investing Cash Flow12.28M-32.70M1.15B124.49M10.72M
Financing Cash Flow-2.50M-198.93M-758.81M91.86M263.08M

Theravance Biopharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price11.09
Price Trends
50DMA
10.95
Positive
100DMA
10.08
Positive
200DMA
9.70
Positive
Market Momentum
MACD
0.05
Positive
RSI
53.19
Neutral
STOCH
58.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBPH, the sentiment is Positive. The current price of 11.09 is below the 20-day moving average (MA) of 11.24, above the 50-day MA of 10.95, and above the 200-day MA of 9.70, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 53.19 is Neutral, neither overbought nor oversold. The STOCH value of 58.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBPH.

Theravance Biopharma Risk Analysis

Theravance Biopharma disclosed 46 risk factors in its most recent earnings report. Theravance Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Theravance Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$554.51M-31.46%6.11%-37.79%
54
Neutral
$638.90M-216.14%203.23%-80.71%
51
Neutral
$7.39B0.36-62.86%2.36%15.48%-2.68%
48
Neutral
$350.58M-75.39%-35.92%-62.11%
48
Neutral
$584.46M3.33%91657.69%97.21%
40
Neutral
$733.49M-59.11%26.24%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TBPH
Theravance Biopharma
11.21
3.53
45.96%
CAPR
Capricor Therapeutics
8.07
4.19
107.99%
MGTX
Meiragtx Holdings
7.62
3.20
72.40%
KROS
Keros Therapeutics
13.36
-31.05
-69.92%
MNMD
Mind Medicine
9.99
2.31
30.08%

Theravance Biopharma Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Theravance Biopharma Gains Milestone Payment from Viatris
Positive
Jun 26, 2025

On June 26, 2025, Theravance Biopharma announced that Viatris secured regulatory approval from China’s NMPA for YUPELRI® (revefenacin) inhalation solution, marking it as the first once-daily nebulized LAMA for COPD maintenance treatment in China. This approval triggers a $7.5 million milestone payment from Viatris to Theravance, expected in Q3 2025, and positions Theravance for further sales-based milestones and royalties, enhancing its financial standing without incurring commercial costs in China.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Legal Proceedings
Theravance Biopharma Settles Patent Litigation with Eugia
Neutral
Jun 6, 2025

On June 5, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Eugia Pharma to resolve ongoing patent litigation concerning the YUPELRI® inhalation solution. The agreement allows Eugia to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by the U.S. Department of Justice and the Federal Trade Commission, while litigation continues against other ANDA filers.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

M&A TransactionsBusiness Operations and Strategy
Theravance Biopharma Sells Trelegy Royalty Interest to GSK
Neutral
Jun 2, 2025

On May 30, 2025, Theravance Biopharma entered into an agreement with GlaxoSmithKline (GSK) to sell its remaining royalty interest in Trelegy Ellipta for $225 million. This transaction, part of the company’s strategic efforts to maximize shareholder value, follows a previous sale of Trelegy royalty interests in 2022 for $1.1 billion. The deal underscores Theravance Biopharma’s strategy to monetize its assets while retaining rights to potential milestone payments from Royalty Pharma.

The most recent analyst rating on (TBPH) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Shareholder Meetings
Theravance Biopharma Holds 2025 Annual General Meeting
Neutral
May 20, 2025

At the 2025 Annual General Meeting held on May 19, Theravance Biopharma shareholders elected Class II directors and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, a non-binding advisory resolution on executive compensation was approved, reflecting shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (TBPH) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025